{"product_id":"molecular-pharmacology-9780470684443","title":"Molecular Pharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eProvides an introduction to the rapidly expanding field of molecular pharmacology. Adopting a drug target-based, rather than the traditional organ\/system based approach, this book reflects the advances and research trend towards molecular based drug design, derived from a detailed understanding of chemical responses in the body.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“An informative, comprehensive text, it is highly recommended to postgraduates and researchers in both pharmacology and molecular biology.”  (\u003ci\u003eScience Progress\u003c\/i\u003e, 1 March 2014)\u003c\/p\u003e \u003cp\u003e“Overall, it could be the basis of an excellent course for junior pharmacologists in basic science research who need a greater focus on the mechanisms of drug action rather than an encyclopedic survey of clinical drug use.”  (\u003ci\u003eDoody’s\u003c\/i\u003e, 26 July 2013)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface ix  \u003cp\u003eAbbreviations x\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction to Drug Targets and Molecular Pharmacology 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction to molecular pharmacology 1\u003c\/p\u003e \u003cp\u003e1.2 Scope of this textbook 2\u003c\/p\u003e \u003cp\u003e1.3 The nature of drug targets 3\u003c\/p\u003e \u003cp\u003e1.4 Future drug targets 7\u003c\/p\u003e \u003cp\u003e1.5 Molecular pharmacology and drug discovery 11\u003c\/p\u003e \u003cp\u003eReferences 12\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Molecular Cloning of Drug Targets 13\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction to molecular cloning – from DNA to drug discovery 13\u003c\/p\u003e \u003cp\u003e2.2 ‘Traditional’ pharmacology 14\u003c\/p\u003e \u003cp\u003e2.3 The relevance of recombinant DNA technology to pharmacology\/drug discovery 14\u003c\/p\u003e \u003cp\u003e2.4 The ‘cloning’ of drug targets 15\u003c\/p\u003e \u003cp\u003e2.5 What information can DNA cloning provide? 20\u003c\/p\u003e \u003cp\u003e2.6 Comparing the pharmacologic profile of the ‘cloned’ and the ‘native’ drug target 23\u003c\/p\u003e \u003cp\u003e2.7 Reverse pharmacology illustrated on orphan GPCRs 24\u003c\/p\u003e \u003cp\u003e2.8 Summary 27\u003c\/p\u003e \u003cp\u003eReferences 27\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 G Protein-coupled Receptors 31\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction to G protein-coupled receptors 31\u003c\/p\u003e \u003cp\u003e3.2 Heterotrimeric G-proteins 36\u003c\/p\u003e \u003cp\u003e3.3 Signal transduction pathways 40\u003c\/p\u003e \u003cp\u003e3.4 Desensitisation and down-regulation of GPCR signalling 44\u003c\/p\u003e \u003cp\u003e3.5 Constitutive GPCR activity 45\u003c\/p\u003e \u003cp\u003e3.6 Promiscuous G-protein coupling 47\u003c\/p\u003e \u003cp\u003e3.7 Agonist-directed signalling 48\u003c\/p\u003e \u003cp\u003e3.8 Allosteric modulators of GPCR function 49\u003c\/p\u003e \u003cp\u003e3.9 Pharmacological chaperones for GPCRs 50\u003c\/p\u003e \u003cp\u003e3.10 GPCR dimerisation 51\u003c\/p\u003e \u003cp\u003e3.11 GPCR splice variants 63\u003c\/p\u003e \u003cp\u003e3.12 Summary 67\u003c\/p\u003e \u003cp\u003eReferences 67\u003c\/p\u003e \u003cp\u003eUseful Web sites 70\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Ion Channels 71\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 71\u003c\/p\u003e \u003cp\u003e4.2 Voltage-gated ion channels 73\u003c\/p\u003e \u003cp\u003e4.3 Other types of voltage-gated ion channels 89\u003c\/p\u003e \u003cp\u003e4.4 Ligand-gated ion channels 109\u003c\/p\u003e \u003cp\u003e4.5 Summary 125\u003c\/p\u003e \u003cp\u003eReferences 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Transporter Proteins 129\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 129\u003c\/p\u003e \u003cp\u003e5.2 Classification 129\u003c\/p\u003e \u003cp\u003e5.3 Structural analysis of transporters 132\u003c\/p\u003e \u003cp\u003e5.4 Transporter families of pharmacological interest 133\u003c\/p\u003e \u003cp\u003e5.5 Transporters and cellular homeostasis 167\u003c\/p\u003e \u003cp\u003e5.6 Summary 169\u003c\/p\u003e \u003cp\u003eReferences 169\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Cystic Fibrosis: Alternative Approaches to the Treatment of a Genetic Disease 175\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 175\u003c\/p\u003e \u003cp\u003e6.2 Cystic fibrosis transmembrane conductance regulator 179\u003c\/p\u003e \u003cp\u003e6.3 Mutations in CFTR 183\u003c\/p\u003e \u003cp\u003e6.4 Why is cystic fibrosis so common? 184\u003c\/p\u003e \u003cp\u003e6.5 Animal models of Cystic fibrosis 186\u003c\/p\u003e \u003cp\u003e6.6 Pharmacotherapy 186\u003c\/p\u003e \u003cp\u003e6.7 Gene therapy 191\u003c\/p\u003e \u003cp\u003e6.8 Conclusion 195\u003c\/p\u003e \u003cp\u003eReferences 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Pharmacogenomics 201\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Types of genetic variation in the human genome 201\u003c\/p\u003e \u003cp\u003e7.2 Thiopurine S-methyltransferase and K+ channel polymorphisms 202\u003c\/p\u003e \u003cp\u003e7.3 Polymorphisms affecting drug metabolism 204\u003c\/p\u003e \u003cp\u003e7.4 Methods for detecting genetic polymorphisms 209\u003c\/p\u003e \u003cp\u003e7.5 Genetic variation in drug transporters 211\u003c\/p\u003e \u003cp\u003e7.6 Genetic variation in G protein coupled receptors 215\u003c\/p\u003e \u003cp\u003e7.7 Summary 225\u003c\/p\u003e \u003cp\u003eReferences 225\u003c\/p\u003e \u003cp\u003eUseful Web sites 226\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Transcription Factors and Gene Expression 227\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Control of gene expression 227\u003c\/p\u003e \u003cp\u003e8.2 Transcription factors 229\u003c\/p\u003e \u003cp\u003e8.3 CREB 233\u003c\/p\u003e \u003cp\u003e8.4 Nuclear receptors 238\u003c\/p\u003e \u003cp\u003e8.5 Peroxisome proliferator-activated receptors 240\u003c\/p\u003e \u003cp\u003e8.6 Growth factors 247\u003c\/p\u003e \u003cp\u003e8.7 Alternative splicing 247\u003c\/p\u003e \u003cp\u003e8.8 RNA editing 251\u003c\/p\u003e \u003cp\u003e8.9 The importance of non-coding RNAs in gene expression 257\u003c\/p\u003e \u003cp\u003e8.10 Summary 270\u003c\/p\u003e \u003cp\u003eReferences 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Cellular Calcium 277\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 277\u003c\/p\u003e \u003cp\u003e9.2 Measurement of calcium 278\u003c\/p\u003e \u003cp\u003e9.3 The exocrine pancreas 289\u003c\/p\u003e \u003cp\u003e9.4 Calcium signalling in pancreatic acinar cells 292\u003c\/p\u003e \u003cp\u003e9.5 Nuclear calcium signalling 303\u003c\/p\u003e \u003cp\u003e9.6 Conclusions 310\u003c\/p\u003e \u003cp\u003eReferences 311\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Genetic Engineering of Mice 315\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction to genetic engineering 315\u003c\/p\u003e \u003cp\u003e10.2 Genomics and the accumulation of sequence data 315\u003c\/p\u003e \u003cp\u003e10.3 The mouse as a model organism 318\u003c\/p\u003e \u003cp\u003e10.4 Techniques for genetic engineering 319\u003c\/p\u003e \u003cp\u003e10.5 Examples of genetically-engineered mice 332\u003c\/p\u003e \u003cp\u003e10.6 Summary 334\u003c\/p\u003e \u003cp\u003eReferences 334\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Signalling Complexes: Protein-protein Interactions and Lipid Rafts 339\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction to cell signalling complexes 339\u003c\/p\u003e \u003cp\u003e11.2 Introduction to GPCR interacting proteins 340\u003c\/p\u003e \u003cp\u003e11.3 Methods used to identify GPCR interacting proteins 340\u003c\/p\u003e \u003cp\u003e11.4 Functional roles of GPCR interacting proteins 345\u003c\/p\u003e \u003cp\u003e11.5 GPCR signalling complexes 348\u003c\/p\u003e \u003cp\u003e11.6 GPCR and ion channel complexes 355\u003c\/p\u003e \u003cp\u003e11.7 Ion channel signalling complexes 356\u003c\/p\u003e \u003cp\u003e11.8 Development of pharmaceuticals that target GPCR interacting proteins 356\u003c\/p\u003e \u003cp\u003e11.9 Development of pharmaceuticals that target protein-protein interactions 356\u003c\/p\u003e \u003cp\u003e11.10 Lipid rafts 357\u003c\/p\u003e \u003cp\u003e11.11 Receptor-mediated endocytosis 361\u003c\/p\u003e \u003cp\u003e11.12 Summary 364\u003c\/p\u003e \u003cp\u003eReferences 364\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Recombinant Proteins and Immunotherapeutics 367\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction to immunotherapeutics 367\u003c\/p\u003e \u003cp\u003e12.2 Historical background of immunotherapeutics 368\u003c\/p\u003e \u003cp\u003e12.3 Basis of immunotherapeutics 368\u003c\/p\u003e \u003cp\u003e12.4 Types of immunotherapeutics 369\u003c\/p\u003e \u003cp\u003e12.5 Humanisation of antibody therapy 372\u003c\/p\u003e \u003cp\u003e12.6 Immunotherapeutics in clinical practice 376\u003c\/p\u003e \u003cp\u003e12.7 Advantages and disadvantages of immunotherapy 378\u003c\/p\u003e \u003cp\u003e12.8 The future 379\u003c\/p\u003e \u003cp\u003e12.9 Summary 380\u003c\/p\u003e \u003cp\u003eReferences 380\u003c\/p\u003e \u003cp\u003eGlossary 381\u003c\/p\u003e \u003cp\u003eIndex 403\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49525387854167,"sku":"9780470684443","price":139.93,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/molecular-pharmacology-9780470684443","provider":"Book Curl","version":"1.0","type":"link"}